### Table of Contents

#### Highlights of This Issue 1973

**SPECIAL FEATURES**

**CCR 20th Anniversary Commentary**

1975  
CCR 20th Anniversary Commentary: Setting the Stage for Nanoparticle Albumin-Bound Paclitaxel—How Far Science Has Come  
Sami I. Bashour and Nuhad K. Ibrahim

**CCR Translations**

1978  
PLEKHA5: A Key to Unlock the Blood–Brain Barrier?  
Sylvia C. Eisele, Corey M. Gill, Ganesh M. Shankar, and Priscilla K. Brastianos  
See related article, p. 2138

1981  
The Yin and Yang of Alloreactivity: Chronic Graft-versus-Host Disease and Leukemia Relapse  
Saar Gill  
See related article, p. 2020

**CCR New Strategies**

1984  
New Strategies in Glioblastoma: Exploiting the New Biology  
Howard A. Fine

**Molecular Pathways**

1989  
Molecular Pathways: Targeting NRG1 Fusions in Lung Cancer  
Lynnette Fernandez-Cuesta and Roman K. Thomas

1995  
Molecular Pathways: A Novel Approach to Targeting Hypoxia and Improving Radiotherapy  
Efficacy via Reduction in Oxygen Demand  
Alexander Lin and Amit Maity

**Reviews**

2001  
Is This the Time to Introduce Minimal Residual Disease in Multiple Myeloma Clinical Practice?  
Bruto Paiva, Noemi Puig, Ramón García-Sanz, and Jesús F. San Miguel on behalf of the Grupo Español de Mieloma (GEM)/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (PETHEMA) cooperative study groups

2009  
Genomic Landscape of Human Papillomavirus–Associated Cancers  
Maria Rusan, Yvonne Y. Li, and Peter S. Hammerman

**CANCER THERAPY: CLINICAL**

2020  
Impact of Chronic Graft-versus-Host Disease on Late Relapse and Survival on 7,489 Patients after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Leukemia  
See related commentary, p. 1981

**PERSONALIZED MEDICINE AND IMAGING**

2029  
Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial  
Lorraine A. Chantrill, Adnan M. Nagrial, Clare Watson, Amber L. Johns, Mona Martyen-Smith, Skye Simpson, Scott Mead, Marc D. Jones, Jassinder S. Samra, Anthony J. Gill, Nicole Watson, Venessa T. Chin, Jeremy L. Humphris, Angela Chou, Belinda Brown, Adrienne Money, Marina Pajic, Sean M. Grimmond, David K. Chang, David Thomas, Lucille Sebastian, Katrin Sjoquist, Sonia Yip, Nick Pavlakis, Ray Asghari, Sandra Harvey, Peter Grimison, John Simes, and Andrew V. Blanken, on behalf of the Australian Pancreatic Cancer Genome Initiative (APGI) and the Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Clinical Management Committee of the Australasian Gastrointestinal Trials Group (AGITG)

2038  
Polymorphisms in MIR27A Associated with Early-Onset Toxicity in Fluoropyrimidine-Based Chemotherapy  
Ursula Amstutz, Steven M. Offer, Johanna Sistonen, Markus Joerger, Robert B. Diasio, and Carlo R. Largiadèr

2045  
Integrated Genomic Profiling, Therapy Response, and Survival in Adult Acute Myelogenous Leukemia  
Brian Parkin, Peter Ouilllette, Mehmet Yildiz, Kamlai Saiya-Cork, Kerby Shedden, and Sami N. Malek
Table of Contents

2167 IL2 Inducible T-cell Kinase, a Novel Therapeutic Target in Melanoma

2177 Identification of Biological Relevant Minor Histocompatibility Antigens within the B-lymphocyte–Derived HLA-Ligandome Using a Reverse Immunology Approach
Pleun Hombrink, Chopie Hassan, Michel G. D. Kester, Lorenz Jahn, Margot J. Pont, Arnoud H. de Ru, Cornelis A. M. van Bergen, Marieke Griffioen, J. H. Frederik Falkenburg, Peter A. van Veelen, and Mirjam H. M. Heemskerk

LETTERS TO THE EDITOR

2187 RAF plus EGFR Inhibition for BRAF-Mutant Metastatic Colorectal Cancer—Letter
Steven Sorscher

2188 RAF plus EGFR Inhibition for BRAF-Mutant Metastatic Colorectal Cancer—Response
Rona Yaeger and Leonard B. Saltz

RETRACTION

2189 Retraction: Glioma-Associated Cancer-Initiating Cells Induce Immunosuppression

CORRECTIONS

2190 Correction: Associations and Interactions between Ets-1 and Ets-2 and Coregulatory Proteins, SRC-1, AIB1, and NCoR in Breast Cancer

2192 Correction: Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors

ABOUT THE COVER

The cover shows establishment of blood brain barrier (BBB) tight junctions. Immunofluorescence staining demonstrates ZO-1 expression within the top endothelial layer of an in vitro BBB. For details, see the article by Jilaveanu and colleagues on page 2138 of this issue.